The Association for Molecular Pathology (AMP) published consensus recommendations to aid in the design and validation of clinical TPMT and NUDT15 genotyping assays, promote standardization of testing across different laboratories and improve patient care.
The manuscript, “TPMT and NUDT15 Genotyping Recommendations: A Joint Consensus Recommendation of the Association for Molecular Pathology, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, and Pharmacogenomics Knowledgebase,” was released online ahead of publication in The Journal of Molecular Diagnostics.
The AMP Pharmacogenetics (PGx) Working Group is developing a series of guidelines designed to help standardize clinical testing for frequently used genotyping assays. The latest TPMT and NUDT15 report builds on the earlier recommendations for clinical genotyping of CYP2C19, CYP2C9, CYP2D6, and genes important for warfarin testing. The recommendations should be implemented together with other relevant clinical guidelines such as those issued by the Clinical Pharmacogenetics Implementation Consortium (CPIC), Dutch Pharmacogenetics Working Group (DPWG), Canadian Pharmacogenomics Network for Drug Safety (CPNDS), and the French National Network of Pharmacogenetics, all of which focus primarily on the interpretation of PGx test results and therapeutic recommendations for specific drug–gene pairs.
To read the full manuscript, please visit https://www.jmdjournal.org/action/showPdf?pii=S1525-1578%2822%2900194-5.